---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002978"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:45:16.994733+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026

## Summary
- Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.
- Proceeds to advance Halneuron clinical development and for working capital.
- Offering closed March 14, 2025; Maxim Group LLC acted as sole placement agent.
- Company expects cash runway through Q1 2026; Halneuron Phase 2b CINP interim data planned for Q4 2025.

## SEC filing metadata
- accession: 0001558370-25-002978
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/0001558370-25-002978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/dwtx-20250312x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002978
- JSON: https://secwatch.observer/filing/0001558370-25-002978.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.